Monitoring serum aminoglycoside concentrations in children with amphotericin B nephrotoxicity.
We prospectively studied the effect of amphotericin B therapy on aminoglycoside clearance in 20 consecutive children during the remission-induction phase of chemotherapy for acute myelocytic leukemia. Increases (greater than 50%) in the half-life for aminoglycoside excretion were not associated with antileukemic or aminoglycoside therapy alone but occurred in 12 of 17 children when amphotericin B was added to the antimicrobial regimen. Seven children had impaired aminoglycoside clearance without increases (greater than 50%) in serum creatinine; hence the resulting adjustments in aminoglycoside dosage would not have been made had we relied solely on serial measurements of serum creatinine. Evidence for increased excretion of the renal enzymes N-acetyl-beta-D-glucosaminidase and alanine aminopeptidase during amphotericin B therapy suggested that damage to proximal tubular cells may contribute to the renal impairment that has been associated with this drug. Our findings underscore the value of monitoring serum aminoglycoside concentrations in children being treated with amphotericin B.
D000118:Acetylglucosaminidase / Q000652:urine; D000293:Adolescent; D000617:Aminoglycosides / Q000493:pharmacokinetics*; D000626:Aminopeptidases / Q000652:urine; D000666:Amphotericin B / Q000009:adverse effects*; D018826:CD13 Antigens; D002648:Child; D002675:Child, Preschool; D004359:Drug Therapy, Combination; D005260:Female; D006207:Half-Life; D006801:Humans; D007223:Infant; D007687:Kidney Tubules, Proximal / Q000187:drug effects; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D008297:Male; D008991:Monitoring, Physiologic; D011446:Prospective Studies
D000617:Aminoglycosides; D000666:Amphotericin B; D000118:Acetylglucosaminidase; D000626:Aminopeptidases; D018826:CD13 Antigens